MET and adenocarcinoma: In the adenocarcinoma group, variants in various genes including TP53 (77%), EGFR (48%), PTEN (28%), PIK3CA (30%), IDH2 (25%), BRAF (19%), KRAS (18%), NRAS (12%), HRAS (11%), VHL (11%), RET (11%), MET (11%), and KIT (10%) were identified (Figure 1B).